Summary: In CNBC’s nightly newscast with Shepard Smith, top trauma researcher Rachel Yehuda, Ph.D., explains that “the positive data from the last Phase 3 MDMA trial, I think, is the biggest thing to happen in the field of PTSD since the field of PTSD became a field.”
This report on the results of the first MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for PTSD also includes the personal account of a Phase 2 trial participant, U.S. Army SGT(R) Jonathan Lubecky, as well as the expert perspective of Susan Walker, M.D., a therapist who provided MDMA-assisted therapy in the Phase 3 trial.
Dr. Walker highlights that this therapeutic process is “not MDMA alone—the therapy, too, is a crucial component of it.”
Originally appearing here.